Abstract
A novel series of bis-isoxazole incorporated benzothiazole derivatives has been designed and synthesized. Molecular structures of the compounds have been confirmed by 1H and 13C NMR, and mass spectra. All products have been tested for their in vitro anticancer activity against breast MCF-7 and MDA MB-231, lungs A549, and prostate DU-145 cancer cell lines using the MTT assay and etoposide as a standard drug. Most of the compounds have demonstrated good to moderate activity, and some of those have exhibited more potent activity than etoposide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
